Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | AT-7867 |
Synonyms | |
Therapy Description |
AT7867 is an ATP-competitive inhibitor of AKT1, AKT2, AKT3, PKA, and P70S6K, which inhibits cell proliferation and tumor growth (PMID: 20423992, PMID: 28843156). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AT-7867 | AT7867 | Akt Inhibitor (Pan) 21 AKT Inhibitor (Pan) - ATP competitive 7 PKA Inhibitor 2 S6 Kinase Inhibitor 5 | AT7867 is an ATP-competitive inhibitor of AKT1, AKT2, AKT3, PKA, and P70S6K, which inhibits cell proliferation and tumor growth (PMID: 20423992, PMID: 28843156). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
PIK3CA mutant | Advanced Solid Tumor | sensitive | AT-7867 | Preclinical | Actionable | In a preclinical study, AT-7867 inhibited proliferation in several human tumor cell lines harboring PIK3CA mutations in culture (PMID: 20423992). | 20423992 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|